ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Developing digital health technologies for frontotemporal degeneration.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- In-clinic validation of a smartphone-based finger tapping test for use in neurodegenerative and neurological populations.medRxiv : the preprint server for health sciences · 2026Article
- Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- From fragmented neurotechnologies to closed-loop brain health systems: integrating artificial intelligence, digital health, digital twins, and advanced materials for brain disorders.Frontiers in bioengineering and biotechnology · 2026Article
- Remote, self-administered, smartphone cognitive testing in a registry-based cohort: Feasibility, reliability, and validity findings.medRxiv : the preprint server for health sciences · 2025Article
- Developing digital health technologies for frontotemporal degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Executive anosognosia in progressive supranuclear palsy versus Parkinson's disease.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Frontotemporal degeneration (FTD) is a rare neurodegenerative disease in which patients can present with cognitive, behavioral, motor, and speech impairment. Currently, there are no approved therapies available to slow or halt disease progression. Detection and monitoring of patient symptoms is challenging for this heterogeneous disease and has negatively impacted progress in FTD clinical trials. Rapid technological advancements can promote the development of digital health technologies (DHTs) capable of capturing even the most subtle clinical impairments. DHTs are computing platforms being designed to measure meaningful aspects of disease onset and progression. Here we present some of the numerous tools currently being developed to measure changes in the functional domains that become impaired in FTD, challenges faced by developers, and a proposed roadmap for developing fit-for-purpose DHTs that will aid in the development of effective therapies for FTD. HIGHLIGHTS: DHTs are being developed to assess FTD onset and progression. Tool developers must overcome numerous challenges in creating effective applications. Guidance to tool developers aims to benefit FTD drug development and patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.